VolitionRx shares jump 10.83% intraday after announcing Nu.Q® Cancer assay reimbursement submission in France with HCL support.

Volitionrx surged 10.83% intraday after announcing the preparation of a reimbursement submission for its Nu.Q® Cancer assays in France, supported by the country’s second-largest hospital system, Hospices Civils de Lyon (HCL). The submission, under France’s "Innovative Procedures Outside the Nomenclature" framework, aims to secure coverage for the test, enabling its integration into routine clinical practice for lung cancer management. HCL’s endorsement and the potential for commercialization in a market with 50,000 annual lung cancer diagnoses positioned the news as a major catalyst. The announcement aligns with the company’s strategic focus on expanding Nu.Q®’s adoption, with projected routine use in France by late 2026 if approved. The sharp price increase reflects investor optimism over regulatory progress and future revenue potential.